Literature DB >> 14720527

Admission Troponin T and measurement of ST-segment resolution at 60 min improve early risk stratification in ST-elevation myocardial infarction.

Erik Björklund1, Bertil Lindahl, Per Johanson, Tomas Jernberg, Ann Marie Svensson, Per Venge, Lars Wallentin, Mikael Dellborg.   

Abstract

AIMS: The prognostic value of admission troponin T (tnT) levels and the resolution of the ST-segment elevation in ST-elevation myocardial infarction (STEMI) is well established. However, the combination of these two early available markers for predicting risk has not been evaluated. METHODS AND
RESULTS: We evaluated 516 patients with fibrinolytic treated STEMI from the ASSENT-2 and ASSENT-PLUS studies, which had both admission tnT and ST-monitoring available. We used a prospectively defined cut-off value of tnT of 0.1microg/l. For ST-segment resolution, a cut-off of 50% measured after 60min was used. Both a tnT >/=0.1microg/l (n=116) and ST-segment resolution <50% (n=301) were related to higher one-year mortality, 13% vs 4% (P<0.001) and 8.4% vs 2.8% (P=0.009), respectively. In a multivariate analysis ST-segment resolution was and tnT showed a strong trend to be independently related to mortality. The combination of both further improved risk stratification. The one-year mortality in the group with elevation of tnT and without ST-segment resolution compared to the group without tnT elevation and with ST-segment resolution was 18.2% vs 2.8% (P<0.001).
CONCLUSIONS: Both tnT on admission and ST-segment resolution after 60min are strong predictors of one-year mortality. The combination of both gives additive early information about prognosis and further improves risk stratification.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14720527     DOI: 10.1016/j.ehj.2003.10.025

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  5 in total

1.  Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction.

Authors:  E Björklund; T Jernberg; P Johanson; P Venge; M Dellborg; L Wallentin; B Lindahl
Journal:  Heart       Date:  2005-10-26       Impact factor: 5.994

2.  MicroRNA-208a: a Good Diagnostic Marker and a Predictor of no-Reflow in STEMI Patients Undergoing Primary Percutaneuos Coronary Intervention.

Authors:  Aboubakr Mohamed Salama; Wael Ali Khalil; Manar Al-Zaky; Somia Hassan Abdallah; Nader Talaat Kandil; Ahmed Abdelsabour; Ahmed Mohammed Shaker; Mesbah Taha Hasanein; Giovanni Battista Luciani; Hassan M E Azzazy
Journal:  J Cardiovasc Transl Res       Date:  2020-05-26       Impact factor: 4.132

3.  Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28.

Authors:  Matthew W Sherwood; David A Morrow; Benjamin M Scirica; Songtao Jiang; Christoph Bode; Nader Rifai; Robert E Gerszten; C Michael Gibson; Christopher P Cannon; Eugene Braunwald; Marc S Sabatine
Journal:  Am Heart J       Date:  2010-06       Impact factor: 4.749

4.  Combined Assessments of Biochemical Markers and ST-Segment Resolution Provide Additional Prognostic Information for Patients With ST-Segment Elevation Myocardial Infarction.

Authors:  Jong Shin Woo; Jin Man Cho; Soo Joong Kim; Myeong Kon Kim; Chong Jin Kim
Journal:  Korean Circ J       Date:  2011-07-30       Impact factor: 3.243

5.  Prognostic Value of New-Generation Troponins in ST-Segment-Elevation Myocardial Infarction in the Modern Era: The RUTI-STEMI Study.

Authors:  Germán Cediel; Ferran Rueda; Cosme García; Teresa Oliveras; Carlos Labata; Jordi Serra; Julio Núñez; Vicent Bodí; Marc Ferrer; Josep Lupón; Antoni Bayes-Genis
Journal:  J Am Heart Assoc       Date:  2017-12-23       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.